
## Tamlyn Anne Rautenberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4268849/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on firstâ€line HIV treatment in Uganda and South Africa. HIV Medicine, 2022, 23, 474-484.	2.2	5
2	Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer. BMC Cancer, 2022, 22, 52.	2.6	4
3	Evaluating the cost utility of racecadotril in addition to oral rehydration solution versus oral rehydration solution alone for children with acute watery diarrhea in four low middle-income countries: Egypt, Morocco, Philippines and Vietnam. Journal of Medical Economics, 2022, 25, 274-281.	2.1	1
4	Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa. Annals of Internal Medicine, 2021, 174, 1683-1692.	3.9	9
5	Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new models. Journal of Medical Economics, 2020, 23, 221-227.	2.1	1
6	Health Economic Decision Tree Models of Diagnostics for Dummies: A Pictorial Primer. Diagnostics, 2020, 10, 158.	2.6	7
7	Cost utility, budget impact, and scenario analysis of racecadotril in addition to oral rehydration for acute diarrhea in children in Malaysia. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 169-178.	1.9	7
8	The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates. HIV Clinical Trials, 2017, 18, 149-155.	2.0	16
9	The cost utility and budget impact of adjuvant racecadotril for acute diarrhea in children in Thailand. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 411-422.	1.9	5
10	Methods to construct a step-by-step beginner's guide to decision analytic cost-effectiveness modeling. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 573-581.	1.9	4
11	Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer. Journal of Medical Economics, 2014, 17, 99-110.	2.1	5
12	Letter to the Editor: Author Response. Journal of Medical Economics, 2014, 17, 443-443.	2.1	0
13	Economic Impact of Including Sequential Bevacizumab for the Treatment of Patients with Kirsten Ras Wild Type Unresectable Metastatic Colorectal Cancer in Four Latin American Countries. Value in Health, 2013, 16, A684.	0.3	0
14	PMD30 Short Term Health-Economic Outcomes of Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes: A Cost Comparison Analysis. Value in Health, 2012, 15, A350.	0.3	0
15	Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model. ClinicoEconomics and Outcomes Research, 2012, 4, 109.	1.9	16
16	Cost analysis for cancer subgroups. British Journal of Cancer, 2009, 100, 1513-1513.	6.4	2
17	PCN129 FACTORS AFFECTING ADMINISTRATION REGIMES AND COSTS ASSOCIATED WITH EIGHT FIRST-LINE CHEMOTHERAPEUTIC DRUGS IN SEVEN COMBINATIONS, IN THE TREATMENT OF MNSCLC. Value in Health, 2009, 12, A281-A282.	0.3	0